Gyre Therapeutics, Inc. 8-K Filing Report - Key Insights from February 14, 2025
Here are the key insights extracted from the provided section of the financial report:
- Entity Information:
- Company Name: Gyre Therapeutics, Inc.
- CIK Number: 0001124105
- State of Incorporation: Delaware (DE)
- SEC File Number: 000-51173
- Employer Identification Number (EIN): 56-2020050
- Address: 12770 High Bluff Drive, San Diego, CA 92130
- Contact Phone: 619-949-3681
- Filing Details:
- Filing Type: 8-K
- Filing Date: February 14, 2025
- Stock Information:
- Common Stock Ticker: GYRE
- Exchange: NASDAQ
- Report Context:
- The reporting period for this filing is a single day, February 14, 2025.
- XML Structure:
- The report is structured in XBRL (eXtensible Business Reporting Language), which is commonly used for financial filings to enhance the accessibility and usability of financial data.
Insights:
- Event Driven Filing: The use of Form 8-K suggests that this report is related to a significant event or corporate change that the company is required to disclose.
- Location: The company is based in San Diego, California, which may be relevant for investors considering regional business dynamics.
- Stock Performance: Being listed on NASDAQ, the company is subject to the regulations and market dynamics of a significant U.S. stock exchange, which may affect its valuation and investor interest.
- Future Monitoring: Investors and analysts should monitor subsequent filings and disclosures from Gyre Therapeutics, Inc. for further details on the nature of the events prompting this filing.
This information can provide a foundational understanding for stakeholders regarding the company's recent activities and its operational context.